QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model

Jessica Kalra(University of British Columbia), Marcel B. Bally(BC Cancer Agency)
Breast Cancer Research
May 1, 2009
Cited by 73


Related Papers